

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – April 13, 2011 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. March 9, 2011 DUR Minutes – Vote
 - B. March 10, 2011 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for December 2010
 - B. Retrospective Drug Utilization Review Response for November 2010
 - C. Medication Coverage Activity Audit for March 2011
 - D. Pharmacy Help Desk Activity Audit for March 2011

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

5. **Action Item – Vote to Update Osteoporosis PBPA Criteria and Prior Authorize Prolia™ and Atelvia™ – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

6. **60 Day Notice to Prior Authorize Topical Corticosteroids – See Appendix D.**
 - A. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **30 Day Notice to Prior Authorize Pradaxa[®] – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Advair[®] and Symbicort[®] and 30 Day Notice to Prior Authorize Dulera[®] – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Dulera[®] Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Anti-Migraine Medications and 30 Day Notice to Prior Authorize Sumavel[®] – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details
 - G. Sumavel[®] Product Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

10. **Fiscal Year 2010 Annual Review – See Appendix H.**
 - A. Top 100 Medications by Total Pharmacy Reimbursement
 - B. Top 50 Medications by Number of Pharmacy Claims
 - C. Pharmacy Claims by Therapeutic Category

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Plavix[®] and Effient[®] – See Appendix I.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Market News and Updates
 - D. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

12. **Action Item – Annual Review of Fibromyalgia Medications – See Appendix J.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**

14. **Future Business**

- A. Utilization Review of Diabetes Products
- B. Annual Review of Ophthalmic Antibiotics
- C. Annual Review of Antiemetics
- E. New Product Reviews

14. **Adjournment**